Rafael Holdings, Inc. Class B Common Stock (RFL)
Rafael Holdings, Inc. Class B (RFL) is a biopharmaceutical company focused on acquiring, developing, and commercializing innovative medical therapies. The company is involved in advancing treatments in areas such as oncology and ophthalmology, aiming to bring novel solutions to unmet medical needs through research and collaborations.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| December 31, 2009 | $0.02 | 2009-12-18 | 2009-12-22 |
| June 30, 2009 | $0.01 | 2009-06-19 | 2009-06-23 |
| March 31, 2009 | $0.02 | 2009-03-20 | 2009-03-24 |
| December 31, 2008 | $0.14 | 2008-12-19 | 2008-12-23 |
Dividends Summary
- Rafael Holdings, Inc. Class B Common Stock has issued 4 dividend payments over the past 1 years
- The most recent dividend was paid 5742 days ago, on December 31, 2009
- The highest dividend payed out to investors during this period was $0.140558 per share
- The average dividend paid during this period was $0.05 per share.
Company News
B.O.S. Better Online Solutions reported strong Q2 2025 results with 36% revenue growth and 53% net income increase, driven primarily by defense sector demand and a robust supply chain division.
Rafael Holdings announced that CEO Bill Conkling will be stepping down, with Executive Chairman Howard Jonas assuming the CEO role. The company is focused on the development of its lead clinical candidate, Trappsol® Cyclo™, for the treatment of Niemann-Pick Disease Type C1.
Rafael Holdings reported a net loss for Q2 and H1 FY2025 due to unrealized losses on its investment in Cyclo Therapeutics, which it plans to merge with. The company is focused on advancing Cyclo's lead clinical program, Trappsol® Cyclo™, for the treatment of Niemann-Pick Disease Type C1.